PUBLIC COMPANY
save$SGMOSANGAMO THERAPEUTICS, INC
$SGMORichmond, CA, USupdated 2mo ago
Sangamo Therapeutics, Inc. is an American biotechnology company based in Brisbane, California, that develops cell and gene therapies for severe genetic diseases.
community read0 votes
pipeline
2
marketed
0
phase 3
0
catalysts ytd
0
approvals ytd
0
recalls ytd
0
Pipeline(2)
pipeline depth2 products
2Phase 2
Upcoming
no upcoming catalysts on record
Recent(90d)
nothing in the last 90 days
view all catalysts →Active trials
- phase2Safety and Tolerability Study of ST-503 for Refractory Pain Due to Peripheral Neuropathy (Small Fiber Predominant, SFN)
- phase2Dose-Ranging Study of ST-920, an AAV2/6 Human Alpha Galactosidase A Gene Therapy in Subjects With Fabry Disease (STAAR)
- —Long-Term Follow-Up of TX200-TR101 (STEADFAST Long Term)
- —Long - Term Follow Up of Sickle Cell Disease and Beta-thalassemia Subjects Previously Exposed to BIVV003 or ST-400.
- phase2A Study to Assess the Safety, Tolerability, and Efficacy of BIVV003 for Autologous Hematopoietic Stem Cell Transplantation in Patients With Severe Sickle Cell Disease
- —Long-Term Follow-up of Subjects Who Were Treated With ST-920
- phase2Safety & Tolerability Study of Chimeric Antigen Receptor T-Reg Cell Therapy in Living Donor Renal Transplant Recipients
- phase1Ascending Dose Study of Genome Editing by Zinc Finger Nuclease Therapeutic SB-FIX in Subjects With Severe Hemophilia B
Insider activity
source: SEC Form 4🐶 Hiring Signal
News
- Bankrupt Sangamo offloads assets to Lilly, PTC in $161M salePTC Therapeutics emerged as the winning bidder over Astellas for Sangamo Therapeutics’ Fabry disease gene therapy, while Eli Lilly is purchasing the biotech’s prion disease program and several plat…biospace · 1mo ago
Data sources
last refreshed 3m ago
Found something off?
comments(0)
5-min edit window · permanent after that